Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage

• Published in: Cellular and molecular life sciences : CMLS Vol. 62; no. 15; pp. 1671 - 1681
• Main Authors: Voziyan, P A, Hudson, B G
• Format: Journal Article
• Language: English
• Published: Switzerland Springer Nature B.V 01.08.2005; Birkhäuser-Verlag
• Subjects: Aging; Animals; Carbonyl compounds; Cardiovascular disease; Diabetes; Diabetes Complications - drug therapy; Diabetes Complications - etiology; Glycation End Products, Advanced - biosynthesis; Humans; Kidney stones; Maillard Reaction; Oxidation; Oxidative Stress - drug effects; Pathogens; Pathology; Pyridoxamine - chemistry; Pyridoxamine - pharmacology; Pyridoxamine - therapeutic use; Reactive Oxygen Species - metabolism; Review
• ISSN: 1420-682X; 1420-9071
• DOI: 10.1007/s00018-005-5082-7

The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.